BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23339126)

  • 1. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties.
    Sarkozy C; Coiffier B
    Clin Cancer Res; 2013 Apr; 19(7):1660-9. PubMed ID: 23339126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
    Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
    Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
    Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G
    Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of the elderly patient with diffuse large B cell lymphoma.
    Fields PA; Linch DC
    Br J Haematol; 2012 Apr; 157(2):159-70. PubMed ID: 22463486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S; Yu Y; Jun-Min L; Jian-Qing M; Qiu-Sheng C; Yu C; Wei-Li Z; Jian-Hua Y; Hui-Jin Z; Yan W; Li W; Shu C; Zhi-Xiang S
    Ann Hematol; 2009 Sep; 88(9):863-9. PubMed ID: 19205655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
    Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary bone marrow diffuse large B cell lymphoma: a case series and review.
    Chang H; Hung YS; Lin TL; Wang PN; Kuo MC; Tang TC; Wu JH; Dunn P; Shih LY
    Ann Hematol; 2011 Jul; 90(7):791-6. PubMed ID: 21181164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
    Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
    Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.